Re: Amendment to Strategic Advisor AgreementTalaris Therapeutics, Inc. • August 25th, 2023 • Biological products, (no disgnostic substances)
This letter (the “Amendment”) amends the terms of your Strategic Advisor Agreement with Talaris Therapeutics, Inc., (the “Company”), dated May 26, 2023 (the “Advisor Agreement”). Capitalized terms not defined herein shall have the meaning specified in the Advisor Agreement. This Amendment represents the mutual written assent referenced in Section 2 of the Advisor Agreement.
